These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27488872)

  • 21. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
    Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
    Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
    Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
    Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
    Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
    Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment.
    Cai L; Chen J; Lu J; Li Q; Chen X; Zhang L; Wu J; Zheng W; Wang C; Su Z
    Mol Cell Endocrinol; 2021 Sep; 535():111396. PubMed ID: 34271069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
    Yonezawa K; Tamaki N; Kokunai T
    Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.
    Selek A; Halbutoğulları ZSU; Aydemir Çİ; Cetinarslan B; Canturk Z; Tarkun I; Erman G; Subaşı C; Erdal K
    Mol Neurobiol; 2023 May; 60(5):2442-2454. PubMed ID: 36662360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
    BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
    Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
    Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
    Trouillas J; Chevallier P; Remy C; Rajas F; Cohen R; Calle A; Hooghe-Peters EL; Rousset B
    Endocrinology; 1999 Jan; 140(1):13-21. PubMed ID: 9886801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells.
    Rowther FB; Richardson A; Clayton RN; Farrell WE
    Neuroendocrinology; 2010; 91(3):256-67. PubMed ID: 20110659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis.
    Al-Azzawi H; Yacqub-Usman K; Richardson A; Hofland LJ; Clayton RN; Farrell WE
    Endocrinology; 2011 Feb; 152(2):364-73. PubMed ID: 21177832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms.
    Wei Y; La L; Wang L; Batey R; Wang C; Li Y
    J Ethnopharmacol; 2017 May; 204():36-44. PubMed ID: 28396166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay.
    Kojima Y; Arita J; Kuwana N; Kimura F
    Endocr J; 1995 Jun; 42(3):355-60. PubMed ID: 7670564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
    Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
    J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines.
    Wang X; Du Q; Mao Z; Fan X; Hu B; Wang Z; Chen Z; Jiang X; Wang Z; Lei N; Wang H; Zhu Y
    Oncotarget; 2017 Jul; 8(28):45874-45887. PubMed ID: 28501857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic resistance in prolactinoma patients.
    Molitch ME
    Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA expression profile of bromocriptine-resistant prolactinomas.
    Wu ZB; Li WQ; Lin SJ; Wang CD; Cai L; Lu JL; Chen YX; Su ZP; Shang HB; Yang WL; Zhao WG
    Mol Cell Endocrinol; 2014 Sep; 395(1-2):10-8. PubMed ID: 25064468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.